Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NHP544C
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NHP544C is an investigational drug evaluated in clinical research for its effects on prostacyclin response. It has been studied in comparison to rapid-release aspirin to assess its impact on the prostacyclin response to intravenous bradykinin. The specific mechanism of action, chemical structure, and therapeutic class of NHP544C are not detailed in publicly available sources. The primary indication under investigation appears to be related to vascular or platelet function as measured by prostacyclin response[1][2]. No information is available regarding approval status or commercial development.
- Other names
- NHP-544CNHP544CNHP 544CNHP 544-CNHP544-CNHP-544-C
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on NHP544C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NHP544C.